$14.90
-0.07 (-0.47%)
Open$14.99
Previous Close$14.97
Day High$15.25
Day Low$14.39
52W High$18.38
52W Low$4.63
Volume—
Avg Volume362.7K
Market Cap255.73M
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+123.7% upside
Current
$14.90
$14.90
Target
$33.33
$33.33
$30.09
$33.33 avg
$42.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.99M | 20.76M | 15.61M |
| Net Income | 4.98M | 4.98M | 3.68M |
| Profit Margin | 24.9% | 24.0% | 23.6% |
| EBITDA | 7.23M | 8.32M | 5.37M |
| Free Cash Flow | 5.95M | 3.82M | 3.47M |
| Rev Growth | +24.3% | +21.0% | +20.1% |
| Debt/Equity | 0.81 | 0.72 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |